A new study led by researchers at the University of Texas MD Anderson Cancer Center has identified a new mechanism by which cancer cells can spread to the brain. The study, published in the journal Nature Medicine, found that a protein called CD44, which is expressed on the surface of cancer cells, plays a key role in the process of brain metastasis.
Brain metastasis is a common complication of cancer, and it is often fatal. The process of brain metastasis is not fully understood, but it is thought to involve a number of steps, including the detachment of cancer cells from the primary tumor, their migration to the brain, and their growth in the brain.
The new study found that CD44 plays a role in all of these steps. CD44 is a cell surface receptor that binds to a number of ligands, including hyaluronic acid. Hyaluronic acid is a component of the extracellular matrix, which is the material that surrounds cells.
The researchers found that CD44 binding to hyaluronic acid activates a signaling pathway that leads to the increased expression of matrix metalloproteinases (MMPs). MMPs are enzymes that break down the extracellular matrix, and they are known to play a role in the invasion and metastasis of cancer cells.
The researchers also found that CD44 binding to hyaluronic acid leads to the activation of the PI3K/Akt signaling pathway. The PI3K/Akt pathway is a key regulator of cell growth and survival, and it is often dysregulated in cancer cells.
The researchers believe that the activation of the CD44/MMP/PI3K/Akt signaling pathway plays a key role in the process of brain metastasis. They believe that targeting this pathway could be a potential new strategy for preventing or treating brain metastasis.
"Our study provides new insights into the mechanisms of brain metastasis and suggests that targeting the CD44/MMP/PI3K/Akt signaling pathway could be a potential new therapeutic strategy for preventing or treating brain metastasis," said Dr. Rakesh K. Jain, professor and director of the Edwin L. Steele, Jr., Laboratory for Tumor Biology at MD Anderson.
The study was funded by the National Institutes of Health, the Department of Defense, and the Cancer Prevention and Research Institute of Texas.
